Search Results
Oct 28, 2025, 09:34 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma
More news about: Faruqi & Faruqi, LLP
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
breast cancer patients in China. In September 2025, the self-developed denosumab injection (project no.: HLX14), in both 60 mg/mL and 120 mg/1.7 mL presentations, was approved for launch successively in the United States and the European Union, becoming the first domestically developed
More news about: Fosun Pharma
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
investigating the clinical profile of Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH) in relation to weight loss and across diverse patient populations. In addition to semaglutide 2.4 mg data, real-world data will be presented that evaluate the benefit of
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
investigating the clinical profile of Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH) in relation to weight loss and across diverse patient populations. In addition to semaglutide 2.4 mg data, real-world data will be presented that evaluate the benefit of
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Mojo® Energy Pouches Announce New Limited-Edition Cinnamon Churro Flavor
Delivering an indulgent blend of cinnamon and brown sugar in Mojo's signature pouch format, the flavor provides 50mg of caffeine (equivalent to about half a cup of coffee), naturally derived from green tea leaves, with zero sugar and zero calories. Each slider pack
More news about: Mojo Energy Pouches
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI.
More news about: Acurx Pharmaceuticals, Inc.
Oct 28, 2025, 07:01 ET Monster Energy Brings European Favorite Bad Apple to America
for a new generation of energy drink lovers. Smooth, crisp, and perfectly balanced, not too sweet, not too dry and it's made with real sugar with 160mg of caffeine per can, giving fans the juice-powered energy they crave with the flavor they didn't know they needed. "Juice Monster
More news about: Monster Energy
Oct 28, 2025, 06:15 ET Layered Double Hydroxide Market worth $1.22 billion by 2030- Exclusive Report by MarketsandMarkets™
Layered Double Hydroxide Market by Type (Mg-Al, Zn-Al, Ca-Al), Application (Catalysts & Precursors, Additives, Absorbent, Water Treatment), End-Use (Chemicals, Electronics, Construction, Agriculture),
More news about: MarketsandMarkets
Oct 27, 2025, 16:05 ET Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
comparing one 200 mg/2 mL subcutaneous injection to two 100 mg/1 mL injections in participants. The study confirmed that Omvoh single-injection is bioequivalent to the previously approved two-injection regimen.1 Treatment with Omvoh for ulcerative colitis starts with 300-mg IV infusions every
More news about: Eli Lilly and Company
Oct 27, 2025, 16:03 ET BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
For BMN 351, BioMarin's next generation oligonucleotide for Duchenne muscular dystrophy, the company expects to share a clinical update for the 6 mg/kg and 9 mg/kg cohorts by year-end. Growt h
More news about: BioMarin Pharmaceutical Inc.
Oct 27, 2025, 09:00 ET BOTTOMS UP FOR A BOOST: VIVE ORGANIC LAUNCHES TWO NEW WELLNESS SHOTS TO SUPPORT SUSTAINED ENERGY THIS HOLIDAY SEASON
Energy + Focus features 75mg of caffeine, plus L-Theanine and Lion's Mane mushroom to enhance mental clarity. Energy Extra Strength delivers 150mg of caffeine with Cordyceps to power performance. Like all Vive Organic wellness shots,
More news about: Vive Organic
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
antagonists or vedolizumab). Patients received guselkumab 400 mg SC q4w (x3) followed by guselkumab 200 mg SC q4w; or guselkumab 400 mg SC q4w (x3) followed by guselkumab 100 mg SC q8w; or placebo. The maintenance doses in GRAVITI (200 mg SC q4w and 100 mg SC q8w) are the same as those evaluated in the Phase
More news about: Johnson & Johnson
Oct 27, 2025, 07:30 ET Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
At Week 28, icotrokinra demonstrated sustained and clinically meaningful results, with all doses (100 mg, 200 mg and 400 mg) showing higher rates of clinical responsea, clinical remissionb, endoscopic improvementc and histologic-endoscopic
More news about: Johnson & Johnson
Oct 27, 2025, 06:50 ET La nueva cara de la aventura: la RAV4 2026 llega este invierno
(modelo A25A-FXS) que funciona con dos motores-generadores (MG1 y MG2) mediante una transmisión variable continua de tipo planetario para impulsar las ruedas delanteras. El motor, que funciona en conjunto con el motor eléctrico principal (MG2), garantiza un rendimiento ágil, mientras que se logra una eficiencia
More news about: Toyota Motor North America
Oct 27, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
reactions, headache, arthralgia, and elevated liver tests. Omvoh injection is available as a 300 mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer
More news about: Eli Lilly and Company
Oct 26, 2025, 22:58 ET Health Canada Grants Authorization for Leqembi® (lecanemab)
it met its primary endpoint and all key secondary endpoints with statistically significant results. The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.6 Lecanemab
More news about: BioArctic
Oct 26, 2025, 22:56 ET Health Canada Grants Authorization for Leqembi® (lecanemab)
it met its primary endpoint and all key secondary endpoints with statistically significant results. The treatment group was administered lecanemab 10 mg/kg bi-weekly, with participants allocated in a 1:1 ratio to receive either placebo or lecanemab for 18 months.6 Lecanemab
More news about: BioArctic
Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
8.02%, mean baseline body weight: 90.47 kg, mean baseline BMI: 32.98 kg/m2). Participants were randomized in a 1:1 ratio to receive mazdutide 6 mg or semaglutide 1 mg for 32 weeks (active-controlled treatment period). In the extension period, participants originally on mazdutide were assigned to continue
More news about: Innovent Biologics
Oct 26, 2025, 15:00 ET Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting
website. About Cristcot's HCA 90 mg Suppository Cristcot's investigational hydrocortisone acetate (HCA) 90 mg suppository formulation is a novel corticosteroid therapy delivering a small volume suppository
More news about: Cristcot
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
BE MOBILE 2, patients were randomized to BIMZELX (160 mg Q4W; N=128 for BE MOBILE 1 and N=221 for BE MOBILE 2) or to placebo (N=126 for BE MOBILE 1 and N=111 for BE MOBILE 2). Patients initially randomized to placebo were switched to BIMZELX (160 mg Q4W) at Week 16.22 BE MOBILE 1 and BE MOBILE
More news about: UCB
Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
doctor. Dosage Form and Strengths: IMAAVY™ is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection. ABOUT JOHNSON & JOHNSON
More news about: Johnson & Johnson
Oct 24, 2025, 12:18 ET 再鼎醫藥公布Zocilurtatug Pelitecan（前稱ZL-1310）最新一期臨床數據， 顯示其成為同類首創用於小細胞肺癌的靶向DLL3 ADC的潛力，並啟動全球三期注冊研究
泌癌，這兩個項目預計將在明年進入注冊性研究階段。」 本次報告披露了包括1期單藥劑量遞增和劑量擴展階段的共6個劑量組的115例患者（0.8 mg/kg、1.2 mg/kg、1.6 mg/kg、2.0 mg/kg、2.4 mg/kg和2.8 mg/kg）的最新結果，數據截止日為2025年9月15日。其中102例患者至少完成過一次基於實體瘤療效評價標准1.1版（RECIST v1.1）的基線後腫瘤評估。 這項多中心研究的所有入組患者均在含鉑化療後出現疾病進展，90%的患者既往接受過免疫檢查點抑制劑治療後出現疾
More news about: 再鼎醫藥
Oct 24, 2025, 11:38 ET Prêmio Mulheres do Agro 2025 revela iniciativas sustentáveis no agronegócio
social e a sustentabilidade. Já Naiara Kasmin, terceira geração à frente da gestão da Fazenda Campestre, localizada em Varginha (MG), mostra que é possível inovar sem perder a essência. Sua visão empreendedora fez triplicar a produção diária de leite, após uma análise rigorosa de custos
More news about: Bayer
Oct 24, 2025, 09:08 ET Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark's Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically
More news about: Glenmark Pharmaceuticals
Oct 24, 2025, 09:02 ET Ortho Molecular Products Partners with Calocurb® to Launch Calocurb® CLINICAL, an Exclusive, Clinically Proven Appetite Management Solution Only Available Under the Guidance of Licensed Practitioners
plant-based appetite and craving control supplement designed specifically for clinical use. Calocurb® CLINICAL delivers a 250 mg therapeutic dose of Amarasate®, a patented natural bitter hops extract developed over 15 years through a $20 million New Zealand government investment
More news about: Calocurb